JAZZ · Jazz Pharmaceuticals PLC - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $4.27B | $4.07B | $3.83B | $3.66B | $3.09B | $2.36B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $782.74M | $884.00M | $849.66M | $590.45M | $505.75M | $335.38M |
| SG&A | $1.81B | $1.39B | $1.34B | $1.42B | $1.45B | $854.23M |
| Total Operating Expenses | $4.70B | $3.35B | $3.26B | $3.72B | $2.92B | $1.99B |
| D&A | $41.60M | $32.80M | $30.40M | $30.30M | $26.70M | $18.70M |
| Operating Income | ($430.24M) | $716.63M | $578.58M | ($65.53M) | $170.28M | $378.07M |
| Interest Expense | - | - | $32.80M | $32.80M | $89.90M | $76.10M |
| Income Tax | ($272.44M) | ($91.43M) | ($119.91M) | ($158.65M) | $216.12M | $33.52M |
| Net Income | ($356.15M) | $560.12M | $414.83M | ($224.06M) | ($329.67M) | $238.62M |
| EPS - Basic | ($5.84) | $9.06 | $6.55 | ($3.58) | ($5.52) | $4.28 |
| EPS - Diluted | ($5.84) | $8.65 | $6.10 | ($3.58) | ($5.52) | $4.22 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.39B | $2.41B | $1.51B | $881.48M | $591.45M | $1.06B |
| Accounts Receivable | $830.75M | $716.76M | $705.79M | $651.49M | $563.36M | $396.49M |
| Inventory | $416.96M | $480.44M | $597.04M | $714.06M | $1.07B | $95.40M |
| Accounts Payable | $122.06M | $77.87M | $102.75M | $90.76M | $100.30M | $26.95M |
| Current Assets | $4.17B | $4.63B | $3.44B | $2.61B | $2.61B | $2.84B |
| Total Assets | $11.66B | $12.01B | $11.39B | $10.84B | $12.30B | $6.54B |
| Current Liabilities | $2.24B | $1.04B | $1.54B | $933.19M | $809.30M | $653.75M |
| Long-term Debt | $4.33B | $6.08B | $5.11B | $5.69B | $6.02B | $1.85B |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $4.32B | $4.09B | $3.74B | $3.09B | $3.97B | $3.66B |
| Retained Earnings | $646.18M | $1.13B | $878.66M | $733.59M | $830.23M | $1.16B |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $1.36B | $1.40B | $1.09B | $1.27B | $778.51M | $899.65M |
| Investing Cash Flow | ($1.51B) | ($508.19M) | ($163.06M) | ($446.23M) | ($5.21B) | ($1.01B) |
| Financing Cash Flow | ($873.38M) | $20.52M | ($305.25M) | ($529.49M) | $3.97B | $528.07M |
| CapEx | $58.75M | $38.07M | $23.96M | $29.05M | $27.64M | $15.00M |
| Free Cash Flow | $1.30B | $1.36B | $1.07B | $1.24B | $750.87M | $884.64M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -10.1% | 17.6% | 15.1% | -1.8% | 5.5% | 16.0% |
| EBITDA margin | -9.1% | 18.4% | 15.9% | -1.0% | 6.4% | 16.8% |
| Net margin | -8.3% | 13.8% | 10.8% | -6.1% | -10.7% | 10.1% |
| Free cash flow margin | 30.4% | 33.4% | 27.9% | 34.0% | 24.3% | 37.4% |
| FCF / Net income | -3.64 | 2.42 | 2.57 | -5.55 | -2.28 | 3.71 |
| R&D / Revenue | 18.3% | 21.7% | 22.2% | 16.1% | 16.3% | 14.2% |
| SG&A / Revenue | 42.4% | 34.0% | 35.0% | 38.7% | 46.9% | 36.1% |
| Effective tax rate | - | -19.5% | -40.7% | - | - | 12.3% |
| Return on assets | -3.1% | 4.7% | 3.6% | -2.1% | -2.7% | 3.7% |
| Return on equity | -8.2% | 13.7% | 11.1% | -7.3% | -8.3% | 6.5% |
| Return on invested capital | -3.9% | 7.0% | 6.5% | -0.6% | 1.3% | 6.0% |
| Liquidity | ||||||
| Current ratio | 1.86 | 4.46 | 2.24 | 2.79 | 3.23 | 4.34 |
| Quick ratio | 1.67 | 3.99 | 1.85 | 2.03 | 1.90 | 4.20 |
| Cash ratio | 0.62 | 2.32 | 0.98 | 0.94 | 0.73 | 1.62 |
| Leverage | ||||||
| Debt / Equity | 1.00 | 1.48 | 1.37 | 1.85 | 1.52 | 0.51 |
| Debt / Assets | 0.37 | 0.51 | 0.45 | 0.53 | 0.49 | 0.28 |
| Debt / EBITDA | - | 8.11 | 8.39 | - | 30.56 | 4.66 |
| Interest coverage | - | - | 17.6x | -2.0x | 1.9x | 5.0x |
| Equity multiplier | 2.70 | 2.93 | 3.05 | 3.51 | 3.10 | 1.79 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.37 | 0.34 | 0.34 | 0.34 | 0.25 | 0.36 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 71d | 64d | 67d | 65d | 66d | 61d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 14.2x | 20.2x | - | - | 39.1x |
| P / B | 2.4x | 2.0x | 2.4x | 3.2x | 1.9x | 2.5x |
| P / S | 2.4x | 2.0x | 2.3x | 2.7x | 2.5x | 3.9x |
| EV / EBITDA | - | 15.7x | 20.5x | - | 66.2x | 25.5x |
| Growth | ||||||
| Revenue growth (YoY) | 4.9% | 6.1% | 4.8% | 18.3% | 30.9% | 9.3% |
| Revenue CAGR (3y) | 5.3% | 9.6% | 17.5% | 19.2% | 27.6% | 13.4% |
| Revenue CAGR (5y) | 12.5% | 13.5% | 20.8% | 17.7% | 15.8% | 12.3% |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 23.9% | - | - | -55.0% | -29.0% |
| Net income growth (YoY) | - | 35.0% | - | 32.0% | - | -54.4% |
| EPS growth (YoY) | - | 41.8% | - | 35.1% | - | -53.6% |
| EPS CAGR (3y) | - | - | 13.1% | - | - | -19.1% |
| EPS CAGR (5y) | - | -1.0% | -3.5% | - | - | -4.2% |
| FCF growth (YoY) | -4.5% | 27.1% | -14.1% | 65.5% | -15.1% | 20.2% |
| FCF CAGR (5y) | 8.0% | 13.0% | 6.5% | 13.4% | 5.2% | 12.3% |
| Book value growth (YoY) | 5.5% | 9.5% | 21.1% | -22.2% | 8.3% | 17.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$12.54B totalProduct And Services Product Sales Net Of Deductions$4.02B · 32.1%
Total Neuroscience$2.88B · 22.9%
Xywav$1.66B · 13.2%
Total Oncology$1.13B · 9.0%
Epidiolex Epidyolex$1.06B · 8.4%
Rylaze Enrylaze$402.92M · 3.2%
Zepzelca$307.31M · 2.5%
Product And Services Royalties And Contract Revenue$245.74M · 2.0%
High Sodium AGOxybate Product Royalty Revenue$211.72M · 1.7%
Defitelio Defibrotide$199.39M · 1.6%
Vyxeos$146.71M · 1.2%
Xyrem$146.03M · 1.2%
Modeyso$48.04M · 0.4%
Other Royalties And Contract Revenue$34.01M · 0.3%
Ziihera$24.81M · 0.2%
Sativex$16.28M · 0.1%
Other Products$14.17M · 0.1%
Geographic
$4.27B totalUS$3.83B · 89.8%
Europe$341.12M · 8.0%
Other Countries$94.87M · 2.2%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✓Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Jazz Pharmaceuticals plc against the 5 most active filers in the same SIC group.